ACLF（慢性肝不全急性増悪）の世界市場レポート 2025年

ACLF（慢性肝不全急性増悪）市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.8％で38億9,000万米ドルに成長します。予測期間中に予想される成長は、肝サポートデバイスの採用増加、再生医療の進歩、精密医療の重視の高まり、低侵襲治療への需要の高まり、標的治療の開発、新興国市場におけるヘルスケアインフラの拡大、研究開発投資の増加、代謝性疾患の有病率の上昇、官民パートナーシップの強化などに起因すると考えられます。この期間に予想される主な動向には、診断における人工知能の統合、生体工学的肝組織の開発、体外式肝支持デバイスの発展、個別化治療計画のための機械学習の利用、遺伝子編集技術の出現、リキッドバイオプシー技術の進歩、標的ドラッグデリバリーシステムの構築、肝再生のための3Dバイオプリンティングの進歩、ウェアラブル健康モニタリングデバイスの採用、ナノテクノロジーに基づく治療の革新などがあります。

精密医療と個別化医療が重視されるようになったことで、今後数年間、ACLF（慢性肝不全急性増悪）市場の拡大が見込まれます。精密医療と個別化医療は、治療成績を向上させ、治療を改善するために、遺伝的、環境的、ライフスタイル的要因に基づいて個々の患者に合わせた治療を行うものです。こうしたアプローチの利用が増加している背景には、ゲノミクスの進歩、バイオマーカーに基づく診断法の利用可能性の拡大、データ解析技術の向上、より的を絞った効果的な治療法に対する需要の高まりがあります。ACLFの文脈では、精密医療と個別化医療は、患者の遺伝子プロファイル、疾患の重症度、バイオマーカーの洞察に基づいてカスタマイズされた治療を可能にし、転帰を改善し、多臓器不全のリスクを低減する標的治療につながります。例えば、2024年2月、米国を拠点とする非営利団体である個別化医療連合（PMC）は、米国食品医薬品局（FDA）が2023年に新たに承認した個別化医薬品は26品目であり、2022年に承認された12品目から顕著に増加したと報告しました。その結果、精密医療と個別化医療への注目の高まりがACLF市場の成長に大きく寄与しています。

ACLF市場の主要企業は、患者の生存率向上を目的とした革新的な治療薬、再生医療アプローチ、標的薬物療法を開発するため、臨床試験を優先しています。臨床試験は、疾患管理を改善し死亡率を低下させるための新しい治療プロトコル、人工肝臓支持システム、免疫調節療法を検証する上で重要な役割を果たしています。例えば、2024年9月、スペインを拠点とするEUのホライズン資金によるプロジェクトA-TANGOは、英国の複数の肝臓センターで「G-TAK試験」を実施する計画を発表しました。この臨床試験は、アルコール性肝炎とACLFに苦しむ重症患者を支援するためのものです。G-TAKは、炎症を抑制するtoll様受容体4拮抗薬（TAK242）と、肝細胞増殖を促進する顆粒球コロニー刺激因子（G-CSF、TRL9）を組み合わせたコンビナトリアル治療薬であり、ACLFの治療薬となる可能性があります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のACLF（慢性肝不全急性増悪） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のACLF（慢性肝不全急性増悪）市場：成長率分析
• 世界のACLF（慢性肝不全急性増悪）市場の実績：規模と成長, 2019-2024
• 世界のACLF（慢性肝不全急性増悪）市場の予測：規模と成長, 2024-2029, 2034F
• 世界のACLF（慢性肝不全急性増悪）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のACLF（慢性肝不全急性増悪）市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬理学的
• 支持療法
• 世界のACLF（慢性肝不全急性増悪）市場投与方法別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 静脈内（IV）
• 世界のACLF（慢性肝不全急性増悪）市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 外来手術センター
• 専門クリニック
• 世界のACLF（慢性肝不全急性増悪）市場、薬理学のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗生物質
• 抗炎症薬
• 血管収縮薬
• 免疫調節薬
• 抗ウイルス剤
• 世界のACLF（慢性肝不全急性増悪）市場、支持療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 肝臓透析
• 血漿交換
• 栄養サポート
• 機械的人工呼吸器
• 腎代替療法（RRT）

第7章 地域別・国別分析

• 世界のACLF（慢性肝不全急性増悪）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のACLF（慢性肝不全急性増悪）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ACLF（慢性肝不全急性増悪）市場：競合情勢
• ACLF（慢性肝不全急性増悪）市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb
• AstraZeneca plc
• Abbott Laboratories
• GSK plc
• Eli Lilly and Company
• Gilead Sciences Inc
• Novo Nordisk A/S
• Astellas Pharma Inc.
• CSL Behring
• Grifols S.A.
• Lupin Pharmaceutical Limited
• Ferring Pharmaceuticals
• Shire plc
• Gyre Therapeutics Inc.
• Dr. Falk Pharma GmbH

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ACLF（慢性肝不全急性増悪）市場2029：新たな機会を提供する国
• ACLF（慢性肝不全急性増悪）市場2029：新たな機会を提供するセグメント
• ACLF（慢性肝不全急性増悪）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Acute on chronic liver failure (ACLF) is a critical condition marked by acute hepatic decompensation in individuals with underlying chronic liver disease. This decline triggers widespread inflammation, leading to the progressive failure of multiple organs. The condition carries a high mortality risk, necessitating quick diagnosis and aggressive medical intervention.

Treatment options for acute on chronic liver failure (ACLF) primarily consist of pharmacological and supportive care. Pharmacological treatments involve the administration of drugs such as antibiotics, vasopressors, corticosteroids, albumin therapy, and liver-specific medications to manage infections, reduce inflammation, support organ function, and stabilize the patient in preparation for possible liver transplantation. These treatments can be delivered through oral or intravenous (IV) routes, and are provided in settings such as hospitals, ambulatory surgical centers, and specialty clinics.

The acute on chronic liver failure (ACLF) market research report is one of a series of new reports from The Business Research Company that provides acute on chronic liver failure (ACLF) market statistics, including acute on chronic liver failure (ACLF) industry global market size, regional shares, competitors with an acute on chronic liver failure (ACLF) market share, detailed acute on chronic liver failure (ACLF) market segments, market trends and opportunities, and any further data you may need to thrive in the acute on chronic liver failure (ACLF) industry. This acute on chronic liver failure (ACLF) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acute on chronic liver failure (ACLF) market size has grown strongly in recent years. It will grow from $2.68 billion in 2024 to $2.89 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth observed during the historic period can be linked to factors such as the increasing prevalence of chronic liver diseases, heightened awareness about liver health, growing healthcare spending, the development of new therapies, the rising incidence of alcohol-related liver damage, an increase in organ transplant procedures, advancements in critical care, a growing aging population, and expanded research into the mechanisms of liver failure.

The acute on chronic liver failure (ACLF) market size is expected to see strong growth in the next few years. It will grow to $3.89 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The anticipated growth during the forecast period can be attributed to the increasing adoption of liver support devices, advancements in regenerative medicine, a growing emphasis on precision medicine, rising demand for minimally invasive treatments, the development of targeted therapies, the expansion of healthcare infrastructure in emerging markets, increased investment in research and development, the rising prevalence of metabolic disorders, and the strengthening of public-private partnerships. Key trends expected in this period include the integration of artificial intelligence in diagnostics, the development of bioengineered liver tissue, advancements in extracorporeal liver support devices, the use of machine learning for personalized treatment plans, the emergence of gene editing technologies, progress in liquid biopsy techniques, the creation of targeted drug delivery systems, advancements in 3D bioprinting for liver regeneration, the adoption of wearable health monitoring devices, and innovations in nanotechnology-based therapies.

The growing emphasis on precision and personalized medicine is expected to drive the expansion of the acute-on-chronic liver failure (ACLF) market in the coming years. Precision and personalized medicine involve tailoring treatments to individual patients based on genetic, environmental, and lifestyle factors to enhance outcomes and improve care. The increasing use of these approaches is attributed to advancements in genomics, the growing availability of biomarker-based diagnostics, improved data analytics technologies, and the rising demand for more targeted and effective therapies. In the context of ACLF, precision and personalized medicine enable customized treatments based on a patient's genetic profile, disease severity, and biomarker insights, leading to targeted therapies that improve outcomes and reduce the risk of multi-organ failure. For example, in February 2024, the Personalized Medicine Coalition (PMC), a U.S.-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a notable increase from the 12 approved in 2022. As a result, the increasing focus on precision and personalized medicine is significantly contributing to the growth of the ACLF market.

Leading companies in the ACLF market are prioritizing clinical trials to develop innovative therapeutics, regenerative medicine approaches, and targeted drug therapies aimed at enhancing patient survival rates. Clinical trials play a vital role in validating new treatment protocols, artificial liver support systems, and immunomodulatory therapies to improve disease management and lower mortality rates. For instance, in September 2024, A-TANGO, a Spain-based EU Horizon-funded project, announced plans to conduct the "G-TAK trial" across multiple liver centers in the UK. This trial is designed to assist critically ill patients suffering from alcoholic hepatitis and ACLF. G-TAK is a combinatorial therapy that includes a toll-like receptor 4 antagonist (TAK242) to reduce inflammation, combined with granulocyte colony-stimulating factor (G-CSF, TRL9) to promote hepatocyte proliferation, thereby offering a potential treatment for ACLF.

In September 2022, Genfit, a France-based late-stage biopharmaceutical company, acquired Versantis for $116 million. This acquisition reinforces Genfit's position in the ACLF market by incorporating a clinically advanced asset with promising Phase Ib and preclinical data, expanding its liver disease pipeline, and utilizing Versantis' expertise to accelerate research and development efforts. Versantis, a Switzerland-based clinical-stage biotechnology company, focuses on addressing the growing unmet medical needs in liver diseases, including ACLF.

Major players in the acute on chronic liver failure (aclf) market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb, AstraZeneca plc, Abbott Laboratories, GSK plc, Eli Lilly and Company, Gilead Sciences Inc, Novo Nordisk A/S, Astellas Pharma Inc., CSL Behring, Grifols S.A., Lupin Pharmaceutical Limited, Ferring Pharmaceuticals, Shire plc, Gyre Therapeutics Inc., Dr. Falk Pharma GmbH, Genfit, eGenesis Inc., Conatus Pharmaceuticals Inc., Cellaion SA, Rheacell GmbH & Co. KG, Martin Pharmaceuticals Inc.

North America was the largest region in the acute on chronic liver failure (ACLF) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in acute on chronic liver failure (ACLF) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acute on chronic liver failure (ACLF) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acute on chronic liver failure (ACLF) market consists of revenues earned by entities by providing services such as diagnostic evaluations, intensive care management, liver function monitoring, hemodialysis, extracorporeal liver support therapies, nutritional support, palliative care and liver transplantation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute on chronic liver failure (ACLF) market also includes sales of diagnostic tools and liver support devices aimed at managing disease progression and improving patient outcomes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acute On Chronic Liver Failure (ACLF) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute on chronic liver failure (aclf) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acute on chronic liver failure (aclf) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acute on chronic liver failure (aclf) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type Of Treatment: Pharmacological; Supportive Care
• 2) By Mode Of Administration: Oral; Intravenous (IV)
• 3) By End-User: Hospitals; Ambulatory Surgical Centers; Specialty Clinics
• Subsegments:
• 1) By Pharmacological: Antibiotics; Anti-inflammatory Drugs; Vasopressors; Immunomodulators; Antiviral Agents
• 2) By Supportive Care: Liver Dialysis; Plasma Exchange; Nutritional Support; Mechanical Ventilation; Renal Replacement Therapy (RRT)
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Bayer AG; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Acute On Chronic Liver Failure (ACLF) Market Characteristics

3. Acute On Chronic Liver Failure (ACLF) Market Trends And Strategies

4. Acute On Chronic Liver Failure (ACLF) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Acute On Chronic Liver Failure (ACLF) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Acute On Chronic Liver Failure (ACLF) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Acute On Chronic Liver Failure (ACLF) Market Growth Rate Analysis
• 5.4. Global Acute On Chronic Liver Failure (ACLF) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Acute On Chronic Liver Failure (ACLF) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Acute On Chronic Liver Failure (ACLF) Total Addressable Market (TAM)

6. Acute On Chronic Liver Failure (ACLF) Market Segmentation

• 6.1. Global Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmacological
• Supportive Care
• 6.2. Global Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous (IV)
• 6.3. Global Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• 6.4. Global Acute On Chronic Liver Failure (ACLF) Market, Sub-Segmentation Of Pharmacological, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antibiotics
• Anti-inflammatory Drugs
• Vasopressors
• Immunomodulators
• Antiviral Agents
• 6.5. Global Acute On Chronic Liver Failure (ACLF) Market, Sub-Segmentation Of Supportive Care, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Liver Dialysis
• Plasma Exchange
• Nutritional Support
• Mechanical Ventilation
• Renal Replacement Therapy (RRT)

7. Acute On Chronic Liver Failure (ACLF) Market Regional And Country Analysis

• 7.1. Global Acute On Chronic Liver Failure (ACLF) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Acute On Chronic Liver Failure (ACLF) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Acute On Chronic Liver Failure (ACLF) Market

• 8.1. Asia-Pacific Acute On Chronic Liver Failure (ACLF) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Acute On Chronic Liver Failure (ACLF) Market

• 9.1. China Acute On Chronic Liver Failure (ACLF) Market Overview
• 9.2. China Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Acute On Chronic Liver Failure (ACLF) Market

• 10.1. India Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Acute On Chronic Liver Failure (ACLF) Market

• 11.1. Japan Acute On Chronic Liver Failure (ACLF) Market Overview
• 11.2. Japan Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Acute On Chronic Liver Failure (ACLF) Market

• 12.1. Australia Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Acute On Chronic Liver Failure (ACLF) Market

• 13.1. Indonesia Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Acute On Chronic Liver Failure (ACLF) Market

• 14.1. South Korea Acute On Chronic Liver Failure (ACLF) Market Overview
• 14.2. South Korea Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Acute On Chronic Liver Failure (ACLF) Market

• 15.1. Western Europe Acute On Chronic Liver Failure (ACLF) Market Overview
• 15.2. Western Europe Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Acute On Chronic Liver Failure (ACLF) Market

• 16.1. UK Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Acute On Chronic Liver Failure (ACLF) Market

• 17.1. Germany Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Acute On Chronic Liver Failure (ACLF) Market

• 18.1. France Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Acute On Chronic Liver Failure (ACLF) Market

• 19.1. Italy Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Acute On Chronic Liver Failure (ACLF) Market

• 20.1. Spain Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Acute On Chronic Liver Failure (ACLF) Market

• 21.1. Eastern Europe Acute On Chronic Liver Failure (ACLF) Market Overview
• 21.2. Eastern Europe Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Acute On Chronic Liver Failure (ACLF) Market

• 22.1. Russia Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Acute On Chronic Liver Failure (ACLF) Market

• 23.1. North America Acute On Chronic Liver Failure (ACLF) Market Overview
• 23.2. North America Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Acute On Chronic Liver Failure (ACLF) Market

• 24.1. USA Acute On Chronic Liver Failure (ACLF) Market Overview
• 24.2. USA Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Acute On Chronic Liver Failure (ACLF) Market

• 25.1. Canada Acute On Chronic Liver Failure (ACLF) Market Overview
• 25.2. Canada Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Acute On Chronic Liver Failure (ACLF) Market

• 26.1. South America Acute On Chronic Liver Failure (ACLF) Market Overview
• 26.2. South America Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Acute On Chronic Liver Failure (ACLF) Market

• 27.1. Brazil Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Acute On Chronic Liver Failure (ACLF) Market

• 28.1. Middle East Acute On Chronic Liver Failure (ACLF) Market Overview
• 28.2. Middle East Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Acute On Chronic Liver Failure (ACLF) Market

• 29.1. Africa Acute On Chronic Liver Failure (ACLF) Market Overview
• 29.2. Africa Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Acute On Chronic Liver Failure (ACLF) Market Competitive Landscape And Company Profiles

• 30.1. Acute On Chronic Liver Failure (ACLF) Market Competitive Landscape
• 30.2. Acute On Chronic Liver Failure (ACLF) Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Acute On Chronic Liver Failure (ACLF) Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb
• 31.2. AstraZeneca plc
• 31.3. Abbott Laboratories
• 31.4. GSK plc
• 31.5. Eli Lilly and Company
• 31.6. Gilead Sciences Inc
• 31.7. Novo Nordisk A/S
• 31.8. Astellas Pharma Inc.
• 31.9. CSL Behring
• 31.10. Grifols S.A.
• 31.11. Lupin Pharmaceutical Limited
• 31.12. Ferring Pharmaceuticals
• 31.13. Shire plc
• 31.14. Gyre Therapeutics Inc.
• 31.15. Dr. Falk Pharma GmbH

32. Global Acute On Chronic Liver Failure (ACLF) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acute On Chronic Liver Failure (ACLF) Market

34. Recent Developments In The Acute On Chronic Liver Failure (ACLF) Market

35. Acute On Chronic Liver Failure (ACLF) Market High Potential Countries, Segments and Strategies

• 35.1 Acute On Chronic Liver Failure (ACLF) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Acute On Chronic Liver Failure (ACLF) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Acute On Chronic Liver Failure (ACLF) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer